Highest-materiality recent filing
Tenon Medical regains Nasdaq compliance after $4.2M offering; future risk remains
Received Nasdaq notice on July 17, 2026, confirming regained compliance with $2.5M minimum stockholders' equity requirement.
Tenon Medical believes it regains Nasdaq equity compliance after $4.2M offering
Sold $4.2M of common stock and warrants in public offering on July 1, 2026.
Tenon Medical closes $4.2M public offering of common stock and warrants
Gross proceeds of $4.2M from offering of 11,052,631 shares (or pre-funded warrants) and common warrants to purchase up to 13,263,159 shares at $0.38 per unit.
Tenon Medical raises executive salaries 5%, extends Chairman Ferrari's consulting agreement
CEO Steven Foster base salary increased 5% to $420,000; CFO to $330,750; COO to $304,500 effective March 1, 2026.
Tenon Medical reduces stockholder quorum to 33 1/3% from majority
Board approved Bylaw Amendment No.1 on June 10, 2026, effective immediately.
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Reported stockholders' equity of $1.895M as of March 31, 2026, below Nasdaq's $2.5M minimum.
Tenon Medical Q1 2026 revenue $1.4M (+90% YoY), gross margin expands to 68.5%
Revenue $1.4M, up ~90% YoY from $0.7M; gross profit $0.9M, up ~193% YoY.
Q4 revenue $1.5M (+92% YoY); gross margin improved to 69% from 46%.
Tenon Medical closes $4.3M private placement of senior convertible notes
Aggregate gross proceeds of $4.3M from senior convertible promissory notes with 20% original issue discount.
Nasdaq letter dated Feb 25, 2026: common stock failed to maintain $1.00 bid price for 30 consecutive business days.
Tenon Medical pre-announces Q4 2025 revenue ~$1.5M (+90% YoY); FY 2025 rev ~$3.9M (+20%)
Preliminary Q4 2025 revenue of $1.45M-$1.48M (unaudited), ~90% increase year-over-year.
Tenon Medical closes $2.85M PIPE offering of 2.2M shares and warrants at $1.285/unit
Issued 2,217,904 shares and warrants to purchase same number at combined $1.285/unit; warrants exercisable at $1.16 for 3 years.
Tenon files SiVantage financials; 2024 rev $1.04M, net loss $1.52M
SiVantage 2024 revenue $1,039k, net loss $1,518k; six months ended June 30, 2025 rev $773k, net loss $995k.
Tenon Medical grants 866,642 RSUs to directors and officers, vesting in 2026
Issued 866,642 restricted stock units to directors and officers under 2022 Equity Incentive Plan.
All seven director nominees elected: Ferrari, Foster, Ginn, Hochschuler, Howard, Jacques, Weigle each received >2.48M votes for.
Acquired substantially all assets of SiVantage (SImmetry) and SIMPL Medical on Aug 1, 2025, for cash, stock, and royalties.
Tenon Medical raises $2.5M in registered direct offering and private placement at $2.00/share
Registered direct offering of 1,271,500 shares (or equivalents) at $2.00/share raising ~$2.5M.
Tenon Medical raises ~$1.46M in registered direct offering and private placement at $2.00/share
Gross proceeds ~$1.46M from 733,500 shares (or equivalents) at $2.00/share in registered direct offering.
Tenon Medical enters warrant inducement; existing warrants exercised at $1.25, ~$3M gross proceeds
Existing warrants for 2,445,700 shares exercised at reduced exercise price of $1.25 per share, down from $4.28.
Tenon Medical regains Nasdaq minimum equity compliance after raising ~$9.6M
Received Nasdaq notice on Aug 23, 2024 for non-compliance with $2.5M minimum stockholders' equity (reported $832K as of June 30).
Tenon Medical closes $4.5M public offering of shares and warrants at $3.68/unit
Issued 1,222,850 shares (or pre-funded warrants) plus warrants for 1,222,850 shares at $3.68 per unit.
Tenon Medical raises ~$4.6M via warrant exercise inducement; issues new warrants
Holder exercises Existing Warrants for 1,222,850 shares at $3.55 each, gross proceeds ~$4.6M.
Nasdaq notified Tenon on Sept 9, 2024, that publicly held shares of 490,364 are below the 500,000 minimum required by Listing Rule 5550(a)(4).
Tenon Medical raises $550K via Series B preferred and warrant private placement
Sold 86,454 Series B Preferred shares and warrants for 16,214 common shares at $4.2756, raising $550K.
Tenon Medical raises $550K via Series B Preferred Stock and warrant private placement
Aggregate offering price of $550,000 for 86,454 Series B Preferred shares and warrants to buy 16,214 common shares at $4.2756.
Tenon Medical appoints Kevin Williamson as CFO effective Sept 3, 2024
Appointed Kevin Williamson as CFO, effective Sept 3, 2024, succeeding retiring CFO Steve Van Dick.
Tenon Medical receives Nasdaq delisting notice for failing minimum equity requirement
Stockholders' equity of $832k as of June 30, 2024, below Nasdaq's $2.5M minimum requirement.
All seven director nominees elected with majority support; broker non-votes ~1.2M shares.
Tenon Medical CFO Steven Van Dick to retire effective July 31, 2024
CFO Steven Van Dick to resign effective July 31, 2024; will consult post-resignation.
Tenon Medical receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days
Nasdaq letter dated May 7, 2024, citing 30 consecutive business days below $1.00 minimum bid price from Mar 25 to May 6.
Tenon Medical appoints Kristine Jacques to Board of Directors effective March 25, 2024
Ms. Jacques brings over 35 years of medtech experience, most recently VP & GM at Vivex Biologics.
Tenon Medical Q4 revenue $808k (+192% YoY); FY gross profit turns positive at $1.2M
Q4 revenue $808k, up 192% YoY; FY revenue $2.9M, up 324% YoY.
Tenon Medical raises $2.6M gross in Series A Preferred, retires $1.25M debt
Gross proceeds of ~$2.6M from sale of 172,239 Series A Preferred shares at $15.125/unit and 258,374 warrants.
Tenon Medical stockholders approve amendment to authorize board to issue preferred stock
Proposal 2 approved at special meeting on Jan 30, 2024: 1,243,383 for, 73,920 against, 21,473 abstain.
Frank Fischer resigned from Board and all committees effective Nov 30, 2023, causing non-compliance.
Tenon Medical adjourns special meeting to Jan 30 for preferred stock vote
Meeting adjourned from Jan 8 to Jan 30, 2024 at 1:30pm PT for more votes on Proposal 2.
Tenon Medical stockholders approve reverse split, adjourn meeting for charter amendment vote
Proposal 1 (stock issuance for Series A Preferred and Warrants) approved: 938,808 For, 35,310 Against.
Director Frank Fischer resigns from Tenon Medical board effective Nov 30, 2023
Frank Fischer resigned as director, from the Audit Committee, and as Chairman of the Compensation Committee on Nov 30, 2023.
Tenon Medical raises $1.125M net via 10% secured notes and warrants
Sold $1.25M in secured notes (10% interest, due Nov 21, 2024) with warrants for 45,000 shares at $1.94.
Tenon Medical executes 1-for-10 reverse stock split effective Nov 2, 2023 to meet Nasdaq minimum bid
Reverse split ratio 1:10; each 10 pre-split shares become 1 post-split share.
Tenon Medical appoints Haskell & White as new auditor after Armanino resignation
Armanino resigned effective Sept 30, 2023 or upon new engagement, due to ceasing public company services.
Tenon Medical enters $10M equity financing agreement with Lincoln Park Capital
Enters $10M common stock purchase agreement with Lincoln Park Capital Fund, LLC.
Tenon Medical receives Nasdaq deficiency notice for bid price below $1.00 per share
Nasdaq letter dated July 20, 2023; common stock failed to maintain $1.00 minimum bid for 30 consecutive days (June 6-July 19, 2023).
Tenon Medical files Form 8-K/A to include final warrant exhibit; no substantive changes
Amendment solely adds final Form of Warrant as Exhibit 4.1 and updates exhibit list.
Tenon Medical regains compliance with Nasdaq minimum equity requirement after $4.866M offering
Received Nasdaq non-compliance notice on May 17, 2023 for minimum stockholders' equity of $2.5 million.
Tenon Medical closes $5.6M public offering of 10M units at $0.56
Sold 10,000,000 units at $0.56/unit; each unit consists of one share and two warrants exercisable at $0.56.
Tenon Medical receives Nasdaq delisting notice for stockholders' equity deficiency
Nasdaq notified Tenon Medical on May 17, 2023 of non-compliance with minimum $2.5M stockholders' equity requirement.
Tenon Medical terminates exclusive distributor SpineSource; expects $4.6M Q4 charge
Paid SpineSource $1M cash, plus $85K/mo for 6 months and commissions (20% net sales through 2023, then 10% until $3.6M).
Tenon settles arbitration with Key Medical and former consultant for $1.2M
Pays $1,200,000 to Key Medical to resolve AAA Case No. 01-21-0016-3950 alleging breach of contract.
Tenon Medical Q1 revenue $71K (+373% YoY), net loss $2.4M; closes $16M IPO
Revenue $71,000, up 373% from $15,000 in Q1 2021, driven by 80% increase in surgical procedures.
On August 20, 2024, Tenon Medical, Inc. (the “Company”) entered into an offer letter (the “Letter”) with Kevin Williamson pursuant to which Mr. Williamson was appointed as Chief Financial Officer of the Company, effective as of September 3, 2024.
Steven Van Dick informed Tenon Medical, Inc. (the “Company”) of his decision to retire and as a result, is resigning from his positions as Executive Vice President, Finance and Administration, Chief Financial Officer and Assistant Secretary effective as of July 31, 2024.
On March 25, 2024, the Board of Directors (the “Board”) of Tenon Medical, Inc. (the “Company”) appointed Kristine Jacques as a member of the Board effective as of March 25, 2024.
On November 30, 2023, Frank Fischer informed Tenon Medical, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (“Board”), which was immediately effective.
Max materiality 0.85 · Median 0.60 · Most common event other_material